Earnings Call · Q1 FY2026·2026-05-06

Q1 26EPS -75.00%·Rev n/aQ4 25EPS -1.01%·Rev n/aQ3 25EPS +85.71%·Rev n/aQ2 25EPS +14.29%·Rev n/a⚠ consensus missing

ACADIA PHARMACEUTICALS INC ACAD

Albert Kildani — Investor Relations or Communications

Catherine Owen Adams — Chief Executive Officer

Thomas Garner — EVP, Chief Commercial Officer

Elizabeth Thompson — Head of Research and Development

Mark Schneyer — EVP, CHIEF FINANCIAL OFFICER

+5.0%1d on move date+5.3% vs SPY3d+1.5%5d+3.3%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ACAD calls or request research access.

More ACAD calls Browse calls Request research access